Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration

Nature

Volumn 402, Issue 6762, 1999, Pages 615-622

  Patrick, Gentry N ^a   Zukerberg, Lawrence ^a,c   Nikolic, Margareta ^a,e   De La Monte, Suzanne ^c   Dikkes, Pieter ^d   Tsai, Li Huei ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; PROTEIN SUBUNIT; TAU PROTEIN;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CYTOSKELETON; HUMAN; MICROTUBULE; NERVE DEGENERATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

EID: 0033540060     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/45159     Document Type: Article

References (49)

1. Lew, J., Winkfein, R. J., Paudel, H. K. & Wang, J. H. Brain proline-directed protein kinase is a neurofilament kinase which displays high sequence homology to p34cdc2. J. Biol. Chem. 267, 25922-25926 (1992).
2. Meyerson, M. et al. A family of human cdc2-related protein kinases. EMBO J. 11, 2909-2917 (1992).
3. Lew, J. et al. A brain-specific activator of cyclin-dependent kinase 5. Nature 371, 423-426 (1994).
4. Ishiguro, K. et al. Identification of the 23 kDa subunit of tau protein kinase 11 as a putalive activator of Cdk5 in bovine brain. FEBS Lett. 342, 203-208 (1994).
5. Tsai, L. H., Delalle, I., Caviness, V. S. Jr. Chac, T. & Harlow, E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 371, 419-423 (1994).
6. Nikolic, M., Dudek, H., Kwon, Y. T., Ramos, Y. F. & Tsai, L. H. The Cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. Genes Dev. 10, 816-825 (1996).
7. Paglini, G. et al. Evidence for the participation of the neuron-specific CDK5 activator P35 during laminin-enhanced axonal growth. J. Neurosci. 18, 9858-9869 (1998).
8. Kwon, Y. T., Tsai, L. H. & Crandall, J. K. Callosal axon guidance defects in p35-/- mice. J. Comp. Neurol 415, 218-229 (1999).
9. Kwon, Y. T. & Tsai, L. H. A novel disruption of cortical development in p35(-/-) mice distinct from reeler. J. Comp. Neurol. 395, 510-522 (1998).
10. Chae, T. et al. Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron 18, 29-42 (1997).
11. Ohshima, T. et al. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc. Natl Acad. Sci. USA 93, 11173-11178 (1996).
12. Gilmore, E. C., Ohshima, T., Goffinet, A. M., Kulkarni, A. B. & Herrup, K. Cyclin-dependent kinase 5- deficient mice demonstrate novel developmental arrest in cerebral cortex. J. Neurosci. 18, 6370-6377 (1998).
13. Bibb, J. A. et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402, 669-671 (1999).
14. Fletcher, A. I. et al. Regulation of exocytosis by cyclin-dependent kinase 5 via phosphorylation of Munc 18. J. Biol. Chem. 274, 4027-4035 (1999).
15. Mandelkow, E. M. & Mandelkow, E. Tau in Alzheimer's disease. Trends Cell Biol. 8, 425-427 (1998).
16. Spillantini, M. G. & Goedert, M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 21, 428-433 (1998).
17. Uchida, T. et al. Precursor of Cdk5 activator, the 23 kDa subunit of tau protein kinase II: its sequence and developmental change in brain. FEBS Lett. 355, 35-40 (1994).
18. Biernat, J. et al. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J. 11, 1593-1597 (1992).
19. Poon, R. Y., Lew, J. & Hunter, T. Identification of functional domains in the neuronal Cdk5 activator protein. J. Biol. Chem. 272, 5703-5708 (1997).
20. Nikolic, M., Chou, M. M., Lu, W., Mayer, B. J. & Tsai, L. H. The p35/Cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity. Nature 395, 194-198 (1998).
21. Philpott, A., Porro, E. B., Kirschner, M. W. & Tsai, L. H. The role of cyclin-dependent kinase 5 and a novel regulatory subunit in regulating muscle differentiation and patterning. Genes Dev. 11, 1409-1421 (1997).
22. Patrick, G. N., Zhou, P., Kwon, Y. T., Howley, P. M. & Tsai, L. H. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. J. Biol. Chem. 273, 24057-24064 (1998).
23. Imahori, K. et al. Possible role of tau protein kinases in pathogenesis of Alzheimer's disease. Neurobiol. Aging 19, S93-98 (1998).
24. Baumann, K., Mandelkow, E. M., Biernat, J., Piwnica-Worms, H. & Mandelkow, E. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases Cdk2 and Cdk5. FEBS Lett. 336, 417-424 (1993).
25. Michel, G. et al. Characterization of tau phosphorylation in glycogen synthase kinase-3β and cyclin dependent kinase-5 activator (p23) transfected cells. Biochim. Biophys. Acta 1380, 177-182 (1998).
26. Paudel, H. K. Phosphorylation by neuronal cdc2-like protein kinase promotes dimerization of Tau protein in vitro. J. Biol. Chem. 272, 28328-28334 (1997).
27. Paudel, H. K., Lew, J., Ali, Z. & Wang, J. H. Brain proline-directed protein kinase phosphorylates tau on sites that are abnormally phosphorylated in tau associated with Alzheimer's paired helical filaments. J. Biol. Chem. 268, 23512-23518 (1993).
28. Lovestone, S. et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol. 4, 1077-1086 (1994).
29. Lovestone, S. & Reynolds, C. H. The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78, 309-324 (1997).
30. Pant Veeranna, A. C., Pant, H. C. & Amin, N. Phosphorylation of human high molecular weight neurofilament protein (hNF-H) by neuronal cyclin-dependent kinase 5 (Cdk5). Brain Res. 765, 259-266 (1997).
31. Sun, D., Leung, C. L. & Liem, R. K. H. Phosphorylation of the high molecular weight neurofilament protein (NF-H) by Cdk5 and p35. J. Biol. Chem. 271, 14245-14251 (1996).
32. Guidato, S., Tsai, L. H., Woodgett, J. & Miller, C. C. Differential cellular phosphorylation of neurofilament heavy side-arms by glycogen synthase kinase-3 and cyclin-dependent kinase-5. J. Neurochem. 66, 1698-1706 (1996).
33. Mandelkow, E. M. et al. Tau domains, phosphorylation, and interactions with microtubules. Neurobiol. Aging 16, 355-362; discussion 362-353 (1995).
34. Lee, K. Y., Rosales, J. L., Tang, D. & Wang, J. H. Interaction of cyclin-dependent kinase 5 (Cdk5) and neuronal Cdk5 activator in bovine brain. J. Biol. Chem. 271, 1538-1543 (1996).
35. Ahuja, H. S., Zhu, Y. & Zakeri, Z. Association of cyclin-dependent kinase 5 and its activator p35 with apoptotic cell death. Dev. Genet. 21, 258-267 (1997).
36. Henchcliffe, C. & Burke, R. E. Increased expression of cyclin-dependent kinase 5 in induced apoptotic neuron death in rat substantia nigra. Neurosci. Lett. 230, 41-44 (1997).
37. Shirvan, A. et al. Expression of cell cycle-related genes during neuronal apoptosis: is there a distinct pattern. Neurochem. Res. 23, 767-777 (1998).
38. Zhang, Q., Ahuja, H. S., Zakeri, Z. F. & Wolgemuth, D. J. Cyclin-dependent kinase 5 is associated with apoptotic cell death during development and tissue remodeling. Dev. Biol. 183, 222-233 (1997).
39. Matsubara, M. et al. Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and Cdk5 and its effects on physiological functions. J. Biol. Chem. 271, 21108-21113 (1996).
40. Shuang, R. et al. Regulation of Munc-18/syntaxin 1A interaction by cyclin-dependent kinase 5 in nerve endings. J. Biol. Chem. 273, 4957-4966 (1998).
41. Tsai, L. H., Takahashi, T., Caviness, V. S. Jr & Harlow, E. Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. Development 119, 1029-1040 (1993).
42. Binder, L. I., Frankfurter, A. & Rebhun, L. I. The distribution of tau in the mammalian central nervous system. J. Cell Biol. 101, 1371-1378 (1985).
43. Greenberg, S. G., Davies, P., Schein, J. D. & Binder, L. I. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J. Biol. Chem. 267, 564-569 (1992).
44. Wolozin, B. L., Pruchnicki, A., Dickson, D. W. & Davies, P. A neuronal antigen in the brains of Alzheimer patients. Science 232, 648-650 (1986).
45. Bursztajn, S. et al. Overexpression in neurons of human presenilin-1 or a presenilin-1 familial Alzheimer disease mutant does not enhance apoptosis. J. Neurosci. 18, 9790-9799 (1998).
46. Fix, A. S., Ross, J. F., Stitzel, S. R. & Switzer, R. C. Integrated evaluation of central nervous system lesions: stains for neurons, astrocytes, and microglia reveal the spatial and temporal features of MK-801-induced neuronal necrosis in the rat cerebral cortex. Toxicol. Pathol. 24, 291-304 (1996).
47. Tanaka, T., Iqbal, K., Trenkner, E., Liu, D. J. & Grundke-Iqbal, I. Abnormally phosphorylated tau in SY5Y human neuroblastoma cells. FEBS Lett. 560, 5-9 (1995).
48. Hockenbery, D., Nunez, G., Milliman, C., Schreiber, R. D. & Korsmeyer, S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348, 334-336 (1990).
49. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J. & Greenberg, M. E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270, 1326-1331 (1995).